Title: Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America20120801
Title: Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America20120801
Title: Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America20120801
Title: Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America20120801
Title: Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America20120801
Title: Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America20120801
Title: Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America20120801
Title: Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America20120801
Title: Fidaxomicin inhibits spore production in Clostridium difficile.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America20120801
Title: Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America20120801
Title: New drugs 2012, part 2.
Journal: Nursing20120701
Title: Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists20120601
Title: Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies.
Journal: Future microbiology20120601
Title: Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
Journal: The Lancet. Infectious diseases20120401
Title: Progress with a difficult infection.
Journal: The Lancet. Infectious diseases20120401
Title: Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America20120215
Title: Annual drug update: 2011 in review.
Journal: The Nurse practitioner20120212
Title: Clostridium difficile infection in older adults: a review and update on its management.
Journal: The American journal of geriatric pharmacotherapy20120201
Title: Fidaxomicin for the treatment of Clostridium difficile infections.
Journal: The Annals of pharmacotherapy20120201
Title: Fidaxomicin, a new treatment for Clostridium difficile infections.
Journal: Drugs of today (Barcelona, Spain : 1998)20120201
Title: Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
Journal: Clinical therapeutics20120101
Title: Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price.
Journal: Clinical drug investigation20120101
Title: Fidaxomicin: in Clostridium difficile infection.
Journal: Drugs20111224
Title: Comparative effectiveness of Clostridium difficile treatments: a systematic review.
Journal: Annals of internal medicine20111220
Title: Clostridium difficile infection: clinical spectrum and approach to management.
Journal: Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology20111201
Title: Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America20110901
Title: Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Journal: Pharmacotherapy20110901
Title: Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
Journal: Journal of medical microbiology20110801
Title: Characterization of a sugar-O-methyltransferase TiaS5 affords new Tiacumicin analogues with improved antibacterial properties and reveals substrate promiscuity.
Journal: Chembiochem : a European journal of chemical biology20110725
Title: Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases20110701
Title: Fidaxomicin: first-in-class macrocyclic antibiotic.
Journal: Expert review of anti-infective therapy20110701
Title: Fewer recurrent infections of C. difficile seen with fidaxomicin. This new class of antibiotic--the macrocycles--has a greater sustained response against re-infection than vancomycin.
Journal: Managed care (Langhorne, Pa.)20110701
Title: Fidaxomicin for Clostridium difficile Infection.
Journal: The New England journal of medicine20110512
Title: Fidaxomicin for Clostridium difficile infection.
Journal: The New England journal of medicine20110512
Title: Fidaxomicin versus vancomycin for Clostridium difficile infection.
Journal: The New England journal of medicine20110203
Title: The search for effective treatment of Clostridium difficile infection.
Journal: The New England journal of medicine20110203
Title: Characterization of tiacumicin B biosynthetic gene cluster affording diversified tiacumicin analogues and revealing a tailoring dihalogenase.
Journal: Journal of the American Chemical Society20110202
Title: 'Game changer' antibiotic and others in works for superbug.
Journal: Nature medicine20110101
Title: Rivaroxaban, ticagrelor, and fidaxomicin.
Journal: Journal of the American Pharmacists Association : JAPhA20110101
Title: Management of Clostridium difficile infection: thinking inside and outside the box.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America20101201
Title: A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.
Journal: Microbiology (Reading, England)20101101
Title: New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile.
Journal: Expert opinion on therapeutic patents20101001
Title: Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
Journal: Expert opinion on pharmacotherapy20100601
Title: Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.
Journal: Expert review of anti-infective therapy20100501
Title: Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections.
Journal: Future microbiology20100401
Title: Chinese medicine tongxinluo significantly lowers serum lipid levels and stabilizes vulnerable plaques in a rabbit model.
Journal: Journal of ethnopharmacology20090706
Title: Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.
Journal: The Journal of antimicrobial chemotherapy20081001
Title: Poxton IR, et al. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. Future Microbiol. 2010 Apr;5(4):539-48.
Title: Tannock GW, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology (Reading). 2010 Nov;156(Pt 11):3354-3359.
Title: Ackermann G, Löffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004 Jun;48(6):2280-2.
Title: Ackermann G, et al. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004 Jun;48(6):2280-2.
